{
    "clinical_study": {
        "@rank": "58858", 
        "arm_group": {
            "arm_group_label": "Revlite Laser System", 
            "arm_group_type": "Experimental", 
            "description": "Revlite Laser System for the Treatment of Melasma"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare a hydroquinone skin care regimen alone  to a\n      combination of  Revlite Laser treatment with a hydroquinone skin care regimen for the\n      treatment of melasma."
        }, 
        "brief_title": "A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Melasma", 
        "condition_browse": {
            "mesh_term": "Melanosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with Fitzpatrick Skin Type III-VI\n\n          -  Subjects with mixed (epidermal and dermal) type melasma diagnosed by Wood's Lamp.\n\n          -  Subjects who are over the age of 18 years of age\n\n          -  The subject is willing and able to comply with study instructions and return to the\n             clinic for required visits.\n\n          -  The subject's melasma has persisted for greater than 6 months\n\n        Exclusion Criteria:\n\n          -  The subject is female and pregnant, has been pregnant within the last 3 months, is\n             currently breast feeding or planning a pregnancy during the study period.\n\n          -  The subject has a history of cutaneous photosensitization, porphyria, and\n             hypersensitivity to porphyrins or photodermatosis.\n\n          -  The subject has any skin pathology or condition that could interfere with the\n             evaluation or requires the use of interfering topical or systemic therapy.\n\n          -  The subject has an uncorrected coagulation defect or is currently using\n             anti-coagulation medication (including but not limited to heavy aspirin therapy).\n\n          -  The subject has any condition which, in the investigator's opinion, would make it\n             unsafe for the subject to participate in this research study.\n\n          -  The subject is currently enrolled in an investigational drug or device trial, or has\n             received an investigational drug or been treated with an investigational device\n             within 30 days prior to entering this study.\n\n          -  The subject has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics,\n             phenothiazines, etc.) within a timeframe where photosensitization from these drugs\n             may still be present.\n\n          -  The subject has the need to be exposed to artificial tanning devices or excessive\n             sunlight during the trial.\n\n          -  The subject has had prior treatment with parenteral gold therapy (gold sodium\n             thiomalate).\n\n          -  The subject has Diabetes Type 1 or 2.\n\n          -  The subject has a sensitivity to hydroquinone or Retin-A.\n\n          -  The subject has evidence of a compromised immune system or hepatitis.\n\n          -  Has had microdermabrasion in past 3 months, other laser or Intense Pulsed Light\n             treatment or chemical peels to the face in past 6 months, injectable fillers, topical\n             retinoids, over-the-counter anti-aging products  past 2 weeks.\n\n          -  Has a history of keloids or hypertrophic scarring\n\n          -  Has permanent make-up and/or is unwilling to refrain from using semi-permanent\n             cosmetics during study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110134", 
            "org_study_id": "CYN13-PICO-TOP-MEL-AK"
        }, 
        "intervention": {
            "arm_group_label": "Revlite Laser System", 
            "description": "Revlite Laser System for the Treatment of Melasma", 
            "intervention_name": "Revlite Laser System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10028"
                }, 
                "name": "NY Laser and Skin Care"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma", 
        "overall_official": {
            "affiliation": "Cynosure, Inc.", 
            "last_name": "Patricia Krantz", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Photos will be a taken at baseline and post treatment and then improvement assessed using the Global Aesthetic Improvement Scale", 
            "measure": "Photographic Evaluation using the Global Aesthetic Improvement Scale", 
            "safety_issue": "No", 
            "time_frame": "1 month post last treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110134"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Satisfaction Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "1 month post last treatment"
        }, 
        "source": "Cynosure, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cynosure, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}